Blood Glucose Testing and Diabetes Management

Content

• 1. Overview
  • 1.1 Statement of Report
  • 1.2 About this Report
  • 1.3 Scope of the Report
  • 1.4 Methodology
  • 1.5 Executive Summary
• 2. Diabetes
  • 2.1 Demographics of Diabetes
    • 2.1.1 Worldwide Diabetes Incidence
    • 2.1.2 U.S. Diabetes
  • 2.2 Economics of Diabetes
  • 2.3 Understanding the Metabolic Conditions Underlying and Associated with Diabetes
    • 2.3.1 Pre-Diabetes Syndrome
    • 2.3.2 Metabolic Syndrome
    • 2.3.3 Diabetes and Inflammation
    • 2.3.4 Progression of Diabetes
    • 2.3.5 Complications and Co-Morbidities in Type 2 Diabetes
    • 2.3.6 Hypoglycemia and Treatment
    • 2.3.7 Risk Factors and Diabetes
    • 2.3.8 Cardiovascular Disease Facts
  • 2.4 Glucose Control in Diabetic Patients
  • 2.5 Tight Glucose Control in Treating Diabetes
  • 2.6 Glucose Monitoring Devices
    • 2.6.1 Key Issues were Identified for Glucose Monitoring
    • 2.6.2 Device Description
    • 2.6.3 Precision
    • 2.6.4 Limitations of Existing Glucose Monitoring Products
• 3. Glucose Measurements
  • 3.1 Glucose Monitoring Markets
    • 3.1.1 Overview of Market Segments
      • 3.1.1.1 Over-the-Counter (OTC) Self-Testing Glucose Market
      • 3.1.1.2 Point of Care Glucose Testing Market
      • 3.1.1.3 Physician Office Laboratories (POL) Glucose Testing Market
      • 3.1.1.4 Clinical Laboratory Glucose Testing Market
    • 3.1.2 Market Analysis: Size, Growth, Share and Competitors
      • 3.1.2.1 Worldwide Market
      • 3.1.2.2 U.S. Market
      • 3.1.2.3 European Market
      • 3.1.2.4 Asian Market
      • 3.1.2.4.1 Japanese Market
      • 3.1.2.4.2 China Market
      • 3.1.2.4.3 India Market
      • 3.1.2.5 ROW Markets
  • 3.2 Glucose Analytical Test Methods
    • 3.2.1 Glucose Oxidase
    • 3.2.2 Glucose Hexakinase
    • 3.2.3 Glucose Dehydrogenase Pyrroloquinolinequinone (GDH-PQQ)
    • 3.2.4 Amperometric Biosensors
    • 3.2.5 Interfering Substances
    • 3.2.6 Monitoring HbA1c Levels
    • 3.2.7 Quality Control Criteria
  • 3.3 Reagents and Equipment
    • 3.3.1 Lancets
    • 3.3.2 Blood Glucose Test Kit
    • 3.3.3 Blood Glucose Monitor and Insulin Doser
    • 3.3.4 Diabetes Tracking System
    • 3.3.5 Blood Glucose Sensors
    • 3.3.6 Blood Glucose Reagent Test Strips
    • 3.3.7 Control Solutions and Calibrators
    • 3.3.8 Sharps Devices
    • 3.3.9 Needle Destruction Devices
    • 3.3.10 Urine Strips
    • 3.3.11 Blood Ketone Testing
    • 3.3.12 Voice Operated Glucose Meters
  • 3.4 Glucose Meters
    • 3.4.1 LifeScan (a Johnson & Johnson Company)
    • 3.4.2 Roche Accu-Chek
    • 3.4.3 Bayer
    • 3.4.4 Medisense (Abbott)
    • 3.4.5 Acon Laboratories
    • 3.4.6 HemoCue
    • 3.4.7 Agamatrix, Inc.
    • 3.4.8 AiMedics, Pty Ltd.
    • 3.4.9 Apex Biotechnology Corp.
    • 3.4.10 77 Elektronika Kft.
    • 3.4.11 Arkray, Inc.
    • 3.4.12 Becton Dickinson & Co.
    • 3.4.13 Accurex (India)
    • 3.4.14 Biosens
    • 3.4.15 Axis-Shield
    • 3.3.16 Home Diagnostics, Inc.
    • 3.3.17 Medisys/Hypoguard
    • 3.3.18 Metrika
    • 3.4.19 Biopeak Corp.
    • 3.4.20 BioTex, Inc.
    • 3.4.21 CalistMedical, Inc.
    • 3.4.22 Allmedicus
    • 3.4.23 Diabetech, LP
    • 3.4.24 Diagnostic Devices
    • 3.4.26 DIRAmed LLC
    • 3.4.27 Entelos
    • 3.4.28 Fifty50 Pharmacy
    • 3.4.29 Fluent Biomedical Corp.
    • 3.4.30 Fovi Optics, Inc.
    • 3.4.31 GenExel-Sein, Inc.
    • 3.4.32 GlucoLight Corp.
    • 3.4.33 Glucon Medical Ltd.
    • 3.4.34 GluMetrics LLC
    • 3.4.35 Glucoplus, Inc.
    • 3.4.36 GlySens, Inc.
    • 3.4.37 HMD BiMedical
    • 3.4.38 Hypoguard
    • 3.4.39 Infratec, Inc.
    • 3.4.40 InLight Solutions, Inc.
    • 3.4.41 Insulet Corp.
    • 3.4.42 Integrity Applications
    • 3.4.43 Kumetrix, Inc.
    • 3.4.44 Lein Applied Diagnostics Ltd.
    • 3.4.45 Cholestech
    • 3.4.46 LighTouch Medical, Inc.
    • 3.4.47 LG Electronics
    • 3.4.48 Luminous Medical, Inc.
    • 3.4.49 Menarini Diagnostics
    • 3.4.50 NIR Diagnostics, Inc.
    • 3.4.51 Oculir, Inc.
    • 3.4.52 OrSense Ltd.
    • 3.4.53 Pelikan Technologies, Inc.
    • 3.4.54 Polymer Technology Systems
    • 3.4.55 PreciSense A/S
    • 3.4.56 QuestStar Medical, Inc.
    • 3.4.57 Sensys Medical
    • 3.4.58 Smiths Medical MD, Inc.
    • 3.4.59 TaiDoc Technology Corp.
    • 3.4.60 U.S. Diagnostics
    • 3.4.61 VeraLight, Inc.
    • 3.4.62 Zyvex Corp
    • 3.4.63 Advanced Biosensors
    • 3.4.64 Health HerNetwork, Inc.
    • 3.4.65 IN4 Technology Corporation
    • 3.4.66 Nipro
    • 3.4.67 TecDiagnostics, Inc.
    • 3.4.68 Uchain Industrial Co., Ltd.
    • 3.4.69 GlucoStat System
    • 3.4.70 SanyJunyaku
    • 3.4.71 Diagnosys Medical
  • 3.5 Diagnosing Diabetes Using In VitrLaboratory Tests
    • 3.5.1 New Diagnostic Guidelines
    • 3.5.2 Fasting Plasma Glucose (FPG) Test
    • 3.5.3 Glucose Tolerance Test
    • 3.5.4 Test for Glycosylated Hemoglobin
    • 3.5.5 Fructosamine
    • 3.5.6 Combined Self-Testing Glucose Monitor with Insulin Delivery
  • 3.6 Continuous and Non-invasive Glucose Patient Monitoring
    • 3.6.1 Medtronic MiniMed Continuous Glucose Monitoring System
    • 3.6.2 Cygnus GlucoWatch Biographer
    • 3.6.3 Abbott FreeStyle Continuous Glucose Monitor System
    • 3.6.4 DexCom, Inc. STS Continuous Glucose Monitoring System
    • 3.6.5 Sontra Medical, Inc.
    • 3.6.6 SpectRx
    • 3.6.7 Pendragon Medical
    • 3.6.8 Sensors for Medicine and Science, Inc. (SMSI)
    • 3.6.9 Other Players
    • 3.6.10 Strategies for Developing Non-invasive Continuous Glucose Monitoring
  • 3.7 Glycosylated Hemoglobin Glucose Monitoring
  • 3.8 Clinical Laboratory Instruments
    • 3.8.1 Ultra-Large Throughput Chemistry Analyzers Large-Throughput Analyzers
    • 3.8.2 Large-Throughput Analyzers
    • 3.8.3 Mid-Size Clinical Chemistry Analyzers
    • 3.8.4 Chemistry Analyzers for the Small Volume Market
• 4. Business Trends in Glucose Testing
  • 4.1 Expanding Opportunities in Blood Glucose Monitoring Market
  • 4.2 Home Diabetes Test Kits an Evolving Market
  • 4.3 Competitive Strategies
  • 4.4 Analyses of the Current Market Conditions, Competition and Product Mix
  • 4.5 The New Paradigm
  • 4.6 Mergers of Diagnostic Companies
  • 4.7 Healthcare Cost Controls
  • 4.8 Competition for Services
  • 4.9 Drivers of Clinical Glucose Testing
  • 4.10 Confluence of New Technology
  • 4.11 Trends in Reimbursement Practices
  • 4.12 Managed Care
  • 4.13 Changes in Patient Management
  • 4.14 Satellite Facilities
  • 4.15 Point-of-Care Testing
  • 4.16 Regionalization of Laboratory Care
  • 4.17 Drivers of the Point of Care Testing Sector
  • 4.18 Diagnostic Testing Growth Trends
  • 4.19 PIPE Financing
  • 4.20 Brand Loyalty
  • 4.21 Insurance Coverage a Key Factor
  • 4.22 Medicare Coverage
  • 4.23 Products at Competitive Price Points
  • 4.24 Drugstores Critical tthe Diabetic Care Category
  • 4.25 Drugstore Chains Increasingly Running Diabetes Care Programs
  • 4.26 Co-branding Strategies
• 5. Important Technology Trends
  • 5.1 Biosensor Technology
  • 5.2 Data Management
    • 5.2.1 Information Management Advances
    • 5.2.2 Patient Care Information System Strategy
    • 5.2.3 Connectivity Platforms
      • 5.2.3.1 DataLink Data Management System
      • 5.2.3.2 RALS-Plus
      • 5.2.3.3 LabPortal. com
      • 5.2.3.4 LifeScan Electronic Data Interfaces
      • 5.2.3.5 Computer Software for Home Glucose Meters
      • 5.2.3.6 Health Buddy Systems Monitoring Technologies
      • 5.2.3.7 Medtronics MiniMed Paradigm Glucose Meter
    • 5.2.4 POL Laboratory Data Management
      • 5.2.4.1 Electronic Medical Record Systems and Physician Office Laboratory Data Linking Software
      • 5.2.4.2 Physician Office Laboratory Data Linking Software and Interface tthe Laboratory Information System
    • 5.2.5 Technical Problems of Connectivity
    • 5.2.6 Web-based Data Interface
    • 5.2.7 HIT Competition
    • 5.2.8 FDA Required Software Verification
  • 5.3 Advantages of Connectivity
  • 5.4 Home Care Analysis
  • 5.5 Technology Platform Innovations in Glucose Testing
  • 5.6 Move Away from Central Laboratory
  • 5.7 Trends in Detection and Diagnosis
    • 5.7.1 Minimally-Invasive Devices
    • 5.7.2 Non-invasive Devices Future Developments and Market Strategy
    • 5.7.3 Continuous Test Systems and the Future of Integrated Glucose/Insulin Delivery
• 6. Competitive Analysis of the Glucose Testing Markets
  • 6.1 The Market Players
  • 6.2 Device Categories
  • 6.3 Range of Products
    • 6.3.1 Cost of Testing
    • 6.3.2 Sample Size Required
    • 6.3.3 Sampling Other Areas
    • 6.3.4 Time Until Patient Obtains Results
    • 6.3.5 Enclosed Test Strips
    • 6.3.6 Test Strip Calibration
    • 6.3.7 Built-in Lancing Device
  • 6.4 Data Handling
  • 6.5 New Developments
  • 6.6 Marketing New Features
  • 6.7 Test Strip Sales
  • 6.8 Reimbursement
  • 6.9 Strip Manufacturers' Responses
  • 6.10 Retailers' Responses
  • 6.11 Market Demand and Composition
  • 6.12 Product Mix
    • 6.12.1 LifeScan
    • 6.12.2 Roche Diagnostics
    • 6.12.3 Bayer Diagnostics
    • 6.12.4 Becton Dickinson
    • 6.12.5 Abbott (MediSense)
    • 6.12.6 Other Players
      • 6.12.6.1 HemoCue AB
      • 6.12.6.2 Home Diagnostics, Inc.
      • 6.12.6.3 Medisys Group PLC
      • 6.12.6.4 Polymer Technology Systems, Inc.
      • 6.12.6.5 QuestStar Medical, Inc.
  • 6.13 Devices that Measure Glycohemoglobin
  • 6.14 Adjacent Markets
  • 6.15 Market Drivers and Restraints
  • 6.16 Market and Product Trends
  • 6.17 Increased Market Penetration
  • 6.18 Costs of Doing Business in Europe
  • 6.19 Drivers of European Diagnostics Testing
  • 6.20 European Reimbursement Practices
  • 6.21 Cost Containment in Europe
  • 6.22 Market Overview of Glucose Monitoring
    • 6.22.1 U.S. Market Segment
    • 6.22.2 European Market
    • 6.22.3 Japanese Market
  • 6.23 Competitive Strategies
  • 6.24 Price Competition
  • 6.25 Analyses of the Current Market Conditions, Competition and Product Mix
    • 6.25.1 First-Generation Monitors
    • 6.25.2 Second-Generation Monitors
    • 6.25.3 Third-Generation SMBG Technologies
  • 6.26 Product Overview
    • 6.26.1 LifeScan
  • 6.27 Design of Glucose Testing Devices
  • 6.28 Insulin Delivery Devices
  • 6.29 Key Glucose Testing Sector Developments
  • 6.30 Important M&A Activity
    • 6.30.1 Cygnus, Inc. Divests its Glucose-Monitoring Assets tAnimas Corporation
    • 6.30.2 Bayer Diagnostics Business Splits intTwUnits
    • 6.30.3 Abbott Laboratories Acquires TheraSense, Inc.
    • 6.30.4 Roche Acquires Infusion Systems Division of Disetronic
    • 6.30.5 J&J Acquires Animas Corporation
    • 6.30.6 Medical Devices Pelikan Technologies, Inc.
    • 6.30.7 Medical Services Amerifit Nutrition, Inc.
    • 6.30.8 Owens & Minor, Inc.
    • 6.30.9 Medisys Sells Business tArkray
    • 6.30.10 Cholestech Signs Agreement with Provalis
    • 6.30.11 Bayer Acquires Metrika
    • 6.30.12 Other Deals
  • 6.31 Product Launches
• 7. Government Regulation of Medical Devices
  • 7.1 U.S. Regulations
    • 7.1.1 Importing Medical Devices intthe U.S.
    • 7.1.2 Exporting Medical Devices from the U.S.
  • 7.2 U.K. Regulations
  • 7.3 E.U. Regulations
  • 7.4 French Regulations
  • 7.5 Japanese Regulations
  • 7.6 Korean Regulations
  • 7.7 FDA Regulations and Recalls
  • 7.8 Legal Liability for Glucose Meters
  • 7.9 ISO 9000 Quality System
  • 7.10 Recent Regulatory Approvals
  • 7.11 FDA Labeling Requirements
• 8. Corporate Profiles
  • 8.1 Abbott Diagnostics
  • 8.2 Abbott Laboratories
  • 8.3 Acon Laboratories
  • 8.4 AgaMatrix
  • 8.5 AiMedics Pty Ltd.
  • 8.6 Animas Corp.
  • 8.7 Apex Biotechnology Corporation
  • 8.8 Bayer Corporation
  • 8.9 Biopeak Corporation
  • 8.10 BioTex
  • 8.11 Dexcom, Inc.
  • 8.12 Diabetech, LP
  • 8.13 77 Elektronika Kft.
  • 8.14 Flexsite Diagnostics
  • 8.15 GenExel-Sein, Inc.
  • 8.16 GlucoLight
  • 8.17 Glucon
  • 8.18 GluMetrics, Inc.
  • 8.19 GlySens, Inc.
  • 8.20 Hemocue
  • 8.21 Hypoguard
  • 8.22 Infratec, Inc.
  • 8.23 IN4 Technology
  • 8.24 InLight Solutions
  • 8.25 ITC (International Technidyne Corporation)
  • 8.26 LifeScan Corporation
  • 8.27 MediSense
  • 8.28 Metrika
  • 8.29 NIR Diagnostics
  • 8.30 NiprMedical Corporation
  • 8.31 OrSense Ltd.
  • 8.32 Pelikan Technologies
  • 8.33 Polymer Technology Systems
  • 8.34 PreciSense
  • 8.35 QuestStar Medical
  • 8.36 Roche Diagnostics
  • 8.37 SankyJunyaku
  • 8.38 Sanwa Kagaku KenkyushCo., Ltd.
  • 8.39 Sensys Medical
  • 8.40 SurgiLance
  • 8.41 Smiths Medical MD, Inc.
  • 8.42 SpectRx
  • 8.43 Taidoc Technology
  • 8.44 TecDiagnostics
  • 8.45 U.S. Diagnostics
  • 8.46 VeraLight
• Appendicies
  • Appendix 1: List of Competitors for Glucose Test Meters and Equipment
  • Appendix 2: FDA Proprietary Devices for Measuring Blood Glucose
  • Appendix 3: Overview of FDA Device Regulations
  • Appendix 4: Retail Prices of Glucose Meters
• Index Of Figures
  • Figure 2.1: Demographic Changes in Diabetes Populations in 2010, 2025 and 2050
  • Figure 2.2: How Diabetes Dollars Are Spent in the U.S.
  • Figure 2.3: Overlap Between Individuals Diagnosed as Diabetic According tFasting Plasma Glucose Concentration (ADA Criteria) or the Two-Hour Glucose Value (WHO Criteria)
  • Figure 2.4: Single Day Continuous Blood Glucose Data
  • Figure 3.1: Share of the U.S. Self-Testing Diagnostic Market, 2006
  • Figure 3.2: U.S. Mass-Market Sales of Glucose Testing Kits, 2000-2012
  • Figure 7.1: World Medical Device Markets
  • Figure 7.2: Medical Device Market Share by U.S. Owned Companies
• Index Of Tables
  • Table 2.1: Normal Glucose Values-Fasting State
  • Table 2.2: Population with Diabetes in the World and in Selected Nations, 2000 and 2030
  • Table 2.3: U.S. Population of Diabetics by Ethnic Group
  • Table 2.4: Percentage of U.S. Adults with Diabetes Using Diabetes Medication by Age Group, 2002-2007
  • Table 2.5: Healthcare Utilization by Diabetic Patients
  • Table 2.6: Age-Adjusted Percentage of Adults with Diabetes Using Diabetes Medication by Type of Medication U.S., 2002-2007
  • Table 2.7: Crude and Age-Adjusted Percentage of Adults with Diabetes Using Diabetes Medication, U.S., 2002-2007
  • Table 2.8: Percentages of Adults with Diabetes Using Diabetes Medication by Age, U.S., 1997-2002
  • Table 2.9: Annual Estimated Cost of U.S. Diabetes Care
  • Table 2.10: Leading Ten Diagnoses by Total U.S. Patient Visits, 2007
  • Table 2.11: U.S. Incidence of Diabetes by Age, 2007
  • Table 2.12: Prevalence, Cost and Medicines for Major Diseases in the U.S., 2007
  • Table 2.13: Top Ten Causes of Death in the U.S., 2007
  • Table 2.14: Per-Event Costs of Diabetes Complications
  • Table 2.15: Percentage of Persons with Type 1 Diabetes Experiencing Various Complications
  • Table 2.17: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
  • Table 2.18: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
  • Table 2.19: Worldwide Market for Cardiac Care Therapeutics, 1999-2010
  • Table 2.20: Major Causes of End-Stage Renal Disease
  • Table 2.21: Key Features Considered for Glucose Meter Devices
  • Table 3.1: Laboratory Assessment of Diabetic Vascular Disease
  • Table 3.2: Key Market Drivers for Glucose Testing
  • Table 3.3: Key Customer Segments of Glucose Testing
  • Table 3.4: Demographic Characteristics Home Testing Kit Buyers
  • Table 3.5: Top Brand Preferences for Home Glucose Testing Kits
  • Table 3.6: Instances When Patients Prefer Professional's Glucose Testing
  • Table 3.7: Advantages of a Home Testing Kit
  • Table 3.8: Disadvantages of Using a Home Testing Kit
  • Table 3.9: Popular Shopping Destinations for Buying or Seeking Information on Home Testing Kits
  • Table 3.10: Total Dedicated U.S. Professional Glucose Testing Market, 2000-2012
  • Table 3.11: Point of Care Glucose Testing U.S. (Hospitals), 2000-2012
  • Table 3.12: U.S. POL Glucose Testing, 2000-2012
  • Table 3.13: U.S. Central Lab Glucose Testing (Hospitals and Reference Labs), 2000-2012
  • Table 3.14: Worldwide Central Lab Glucose Testing (Hospitals and Reference Labs), 2000-2012
  • Table 3.15: Worldwide Glucose Self-Testing Market Sales (Meters, Strips, Lancets), 2000-2012
  • Table 3.16: Worldwide Glucose Market for Self-Testing Sales (Meters, Strips, Lancets), 2000-2012
  • Table 3.17: Glucose Market for Self-Testing and POC Devices in the U.S., 2000-2012
  • Table 3.18: U.S. Blood Glucose Reagent Strip Market, 2000-2012
  • Table 3.19: OTC Glucose Meter U.S. Market Share for Blood Glucose Measurements
  • Table 3.20: U.S. Diabetes Glucose Monitoring Market Repeat Retail Replacement Sales Percentages
  • Table 3.21: Top Four Players in the U.S. Blood Glucose Strips Market (Ranked by % Sales), 2006
  • Table 3.22: Leading Blood Glucose Meters and Strips Brands in the U.S. (% Breakdown by Dollar Sales), 2006
  • Table 3.23: European Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
  • Table 3.24: European Glucose Self-Testing Market by Country Market
  • Table 3.25: Asian Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
  • Table 3.26: Japanese Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
  • Table 3.27: Chinese Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
  • Table 3.28: China Blood Glucose Reagent Strip Market, 2000-2012
  • Table 3.29: Indian IVD Market, 2006-2012
  • Table 3.30: Number of Automated Clinical Labs in India, 2004-2012
  • Table 3.31: Indian IVD Market, 2006
  • Table 3.32: Indian Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
  • Table 3.33: Indian Blood Glucose Reagent Strip Market, 2000-2012
  • Table 3.34: ROW Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
  • Table 3.35: Unit Sales of Homecare Lancets in the U.S., 2000-2012
  • Table 3.36: Unit Sales of Lancets in the E.U., 2000-2012
  • Table 3.37: Dollar Sales of Lancets in the U.S., 2000-2012
  • Table 3.38: Dollar Sales of Lancets in the E.U., 2000-2012
  • Table 3.39: Unit Sales of Homecare Glucose Self-testing Lancets in the U.S., 2000-2012
  • Table 3.40: Unit Sales of Homecare Glucose Self-testing Lancets in the E.U., 2000-2012
  • Table 3.41: Competition in the Lancet Market Segment
  • Table 3.42: Technology of Glucose Testing Instruments
  • Table 3.43: Key Features of Reagent Test Strips
  • Table 3.44: Limitations of Urine Glucose Monitoring
  • Table 3.45: Advantages of Urine Glucose Monitoring
  • Table 3.46: Blood Ketone Reading Indications
  • Table 3.47: Customer Priorities-Glucose Meter Self-Testing Market
  • Table 3.48: Accu-Chek Blood Glucose Monitoring Systems
  • Table 3.49: GlucoTrack Comparison and Results
  • Table 3.50: Home Diagnostics' Current Product Portfolio
  • Table 3.51: Relationship of A1c tAverage Whole Blood and Plasma Glucose Levels
  • Table 3.52: Distributors of Glucose Meters
  • Table 3.53: Ultra-Large Clinical Chemistry Analyzers
  • Table 3.54: JEOL Analyzer Comparison
  • Table 3.55: Large Clinical Chemistry Analyzers
  • Table 3.56: Mid-size Clinical Chemistry Analyzers
  • Table 3.57: Small Clinical Chemistry Analyzers
  • Table 4.1: U.S. Diabetes Glucose Monitoring Market Segments
  • Table 4.2: Medicare Billing Guidelines for Multichannel Chemistry Tests
  • Table 5.1: Customized Reports must Support CAP and JCAHO Requirements
  • Table 5.2: RALS-Plus Point of Care Market Share
  • Table 5.3: Applications of RALS Connectivity with POCT Devices
  • Table 6.1: Comparisons of Blood Glucose Monitoring Systems
  • Table 6.2: U.S. Diabetes Glucose Monitoring Market, 2006
  • Table 6.3: Syringes for Administering Insulin
  • Table 6.4: Insulin Pens
  • Table 6.5: Injection Aids
  • Table 6.6: Jet Injectors
  • Table 6.7: External Insulin Pumps
  • Table 6.8: Insulin Delivery Device Market, 2004-2014
  • Table 8.1: Products Marketed by Abbott in the Diagnostic Market
  • Table 8.2: Key Roche Diagnostic Products